Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183803 | 0.99 | ADORA3 (0.51) | ADORA3MAPTLMNAADORA2AADORA2B | |
| SCHEMBL4181911 | 0.84 | MAPT (0.42) | ADORA3MAPTLMNAADORA2AKDM4E | |
| SCHEMBL4175387 | 0.83 | KDM4E (0.49) | ADORA3MAPTLMNAADORA2AADORA2B | |
| SCHEMBL4179942 | 0.83 | SMN1; SMN2 (0.41) | ADORA3MAPTLMNAADORA2AADORA1 | |
| SCHEMBL4180486 | 0.82 | ADORA2A (0.50) | ADORA3MAPTLMNAADORA2AADORA2B | |
| SCHEMBL4164606 | 0.81 | TSHR (0.42) | ADORA3MAPTLMNAKDM4ETSHR | |
| SCHEMBL4169269 | 0.80 | ADORA3 (0.46) | ADORA3MAPTLMNAADORA2AADORA2B | |
| SCHEMBL4181951 | 0.78 | ADORA3 (0.46) | ADORA3MAPTLMNAADORA2AADORA2B | |
| SCHEMBL4171957 | 0.78 | AVPR2 (0.41) | MAPTLMNAP2RX3 | |
| SCHEMBL4181990 | 0.77 | CLPP (0.52) | MAPTP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | claimed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088439-A1 | Diazinane Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| WO-2009041905-A1 | PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009041905-A1 | PTERIDINE COMPOUNDS HAVING ACTIVITY ON THE GABA- RECEPTORS | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088439-A1 | Diazinane Compounds | GABRB1, GRPR, GIPR | ADORA3 322/4885MAPT 3675/4885LMNA 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.